首页 | 本学科首页   官方微博 | 高级检索  
   检索      

一种定量检测人血清高敏C反应蛋白的化学发光免疫方法
引用本文:刘平果,李国强,陈毅歆,罗海峰,黄德党,王颖彬,葛胜祥,张军,夏宁邵.一种定量检测人血清高敏C反应蛋白的化学发光免疫方法[J].生物工程学报,2010,26(8):1150-1156.
作者姓名:刘平果  李国强  陈毅歆  罗海峰  黄德党  王颖彬  葛胜祥  张军  夏宁邵
作者单位:1. 厦门大学附属中山医院,肝胆外科,厦门,361004
2. 厦门大学生命科学学院,国家传染病诊断试剂与疫苗工程技术研究中心,厦门,361005
基金项目:国家高技术研究发展计划 (863计划) (No. 2006AA020905),福建省医学创新课题 (No. 2009-CXB-55) 资助。
摘    要:旨在建立一种可定量检测人血清高敏CRP的化学发光检测方法 (High-sensitivity C-reactive protein quantifiable chemiluminescent immunoassay,hs-CRP CLIA)。首先利用亲和层析和离子交换层析技术从肝硬化病人腹水中纯化出高纯度的天然CRP作为免疫原制备了22株CRP单克隆抗体 (单抗),其中13株单抗在磷酸胆碱配体捕获ELISA中呈阳性,然后利用方正滴定法筛选出单抗10C5和10C11建立了hs-CRP CLIA。试剂盒评估结果显示:该方法对血清中干扰物质IgG、血红蛋白、甘油三酯等无非特异性反应;该方法检测灵敏度高,在0.04~20.38 mg/L范围内定量检测人血清CRP标准品呈良好线性关系 (R2>0.993);该方法准确性高、可重复性好,平均回收率为99%,批内差为4.2%~5.8%,批间差为9.0%~11.5%;该方法与进口商品化高敏CRP ELISA试剂盒平行比较检测90份血清标本,结果显示两者有良好的可比性 (r=0.968)。综上,建立的hs-CRP CLIA是一种准确、可靠、可定量的高灵敏C反应蛋白检测方法,该方法的临床应用,有利于改善我国心脏病风险评估及肠炎性疾病预后判断。

关 键 词:高敏,C反应蛋白,单克隆抗体,化学发光,心血管疾病,肠炎性疾病
收稿时间:2/3/2010 12:00:00 AM

Chemiluminescent immunoassay for high-sensitivity C-reactive protein
Pingguo Liu,Guoqiang Li,Yixin Chen,Haifeng Luo,Dedang Huang,YingbinWang,Shengxiang Ge,Jun Zhang and Ningshao Xia.Chemiluminescent immunoassay for high-sensitivity C-reactive protein[J].Chinese Journal of Biotechnology,2010,26(8):1150-1156.
Authors:Pingguo Liu  Guoqiang Li  Yixin Chen  Haifeng Luo  Dedang Huang  YingbinWang  Shengxiang Ge  Jun Zhang and Ningshao Xia
Institution:Zhongshan Hospital, Xiamen University, Xiamen 361004, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China
Abstract:We developed a high-sensitivity C-reactive protein quantifiable chemiluminescent immunoassay (hs-CRP CLIA). The high-purity native CRP was purified from hepatic cirrhosis patient ascetic fluid by affinity and ion exchange chromatography and used as an immunogen to develop the monoclonal antibodies (mAbs) against CRP. Twenty-two mAbs were identified reactive with CRP in ELISA and 13 of them were reactive in the phosphorycholine ligand capture ELISA. The mAbs 10C5 and 10C11 were selected to develop the hs-CRP CLIA. The linearity and performance of the hs-CRP CLIA was characterized. It was showed not reactive when testing against other serum materials (IgG, hemoglobin and triglyceride). The reliable correlation (R2 > 0.993) was obtained between testing value (RLU/S) and the concentration of human serum CRP calibrator. The linearity fell in the range of 0.04?20.38 mg/L. The assay has good accuracy and reproducibility, the mean recovery was 99% and the precision of the intra- and inter assay was CVs (4.2%?5.8%) and (9.0%?11.5%), respectively. In testing of 90 human sera, this assay performed well and correlated comparably with a commercial hs-CRP ELISA kit. Thus, hs-CRP CLIA is an accurate, reliable, quantifiable assay for detection of high-sensitive C-reactive protein in serum, it may be useful to improve the risk assessment of cardiovascular disease and the prognosis of inflammatory bowel disease.
Keywords:high-sensitivity  C-reactive protein  monoclonal antibody  chemiluminescent  cardiovascular disease  inflammatory bowel disease
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
点击此处可从《生物工程学报》浏览原始摘要信息
点击此处可从《生物工程学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号